









Markets
/
Stocks
/
nasdaq-pgny
/

Progyny Inc

PGNY

18.785USD

+0.135+0.72%

Market hours （ET）Quotes delayed by 15 min

1.61BMarket Cap

30.38P/E TTM



Progyny Inc

18.785

+0.135+0.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Progyny Inc

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Progyny Inc's Score

Industry at a Glance

Industry Ranking

21 / 78

Overall Ranking

107 / 4621

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

28.714

Target Price

+50.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Progyny Inc Highlights

StrengthsRisks

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 48.33% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.17B.

Undervalued

The company’s latest PE is 30.14, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 89.73M shares, decreasing 22.89% quarter-over-quarter.

Held by Robert Olstein

Star Investor Robert Olstein holds 35.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 8.59, which is higher than the Healthcare Providers & Services industry's average of 7.24. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 332.87M, representing a year-over-year increase of 9.47%, while its net profit experienced a year-over-year increase of 3.80%.

Score

Industry at a Glance

Previous score

8.59

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.68

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.52

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.74

Key Metrics

Free cash flow

No Data

Progyny Inc's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 6.79, which is lower than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is 30.14, which is 285.21% below the recent high of 116.10 and 26.61% above the recent low of 22.12.

Score

Industry at a Glance

Previous score

6.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 21/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 7.80, which is higher than the Healthcare Providers & Services industry's average of 7.60. The average price target for Progyny Inc is 30.00, with a high of 32.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

7.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

28.714

Target Price

+50.42%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Progyny Inc

PGNY

Humana Inc

HUM

UnitedHealth Group Inc

UNH

Cigna Group

Elevance Health Inc

ELV

Centene Corp

CNC

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 6.31, which is lower than the Healthcare Providers & Services industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 21.71 and the support level at 16.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Sell

RSI(14)

33.655

Neutral

STOCH(KDJ)(9,3,3)

20.878

Sell

ATR(14)

0.908

High Vlolatility

CCI(14)

-114.343

Sell

Williams %R

86.348

Oversold

TRIX(12,20)

-0.465

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

19.198

Sell

MA10

19.304

Sell

MA20

19.869

Sell

MA50

21.389

Sell

MA100

21.940

Sell

MA200

21.991

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Providers & Services industry's average of 6.96. The latest institutional shareholding proportion is 104.36%, representing a quarter-over-quarter decrease of 3.32%. The largest institutional shareholder is The Vanguard, holding a total of 9.85M shares, representing 11.46% of shares outstanding, with 12.72% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.27M

+2.28%

The Vanguard Group, Inc.

Star Investors

9.85M

+14.59%

Seidenberg (Beth C)

5.35M

+0.13%

Kleiner, Perkins, Caufield & Byers

5.07M

Thrivent Asset Management, LLC

4.89M

-8.63%

Fidelity Management & Research Company LLC

3.23M

+12.49%

State Street Investment Management (US)

2.87M

-1.62%

BlackRock Financial Management, Inc.

2.04M

+147.22%

ArrowMark Colorado Holdings, LLC

1.89M

-14.43%

Fred Alger Management, LLC

1.76M

+38.70%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 6.57, which is higher than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 1.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.